Pembrolizumab Safe, Shows Activity for Advanced Lung Cancer

Share this content:
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced NSCLC.
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced NSCLC.

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC), a new study published online early in The England Journal of Medicine has shown.

For the study, researchers sought to assess the safety and efficacy of pembrolizumab, a programmed cell death 1 (PD-1) inhibitor, as treatment for patients with advanced NSCLC.

Researchers enrolled 495 patients who were enrolled in a phase I study. Participants were assigned to receive pembrolizumab 2 or 10mg/kg every 3 weeks of 10mg/kg every 2 weeks. Researchers also evaluated whether PD-1 ligand 1 (PD-L1) expression level was associated with clinical benefit.

Results showed that the overall objective response rate was 19.4% and the median duration of response was 3.7 months. The median duration of overall survival was 12.0 months.

RELATED: Nivolumab Shows Encouraging Survival Rates in Heavily Pretreated Lung Cancer

The study also showed that PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.

The response rate was 45.2% with a median progression-free survival of 6.3 months and median overall survival had not yet been reached.

In regard to safety, the most common pembrolizumab-associated adverse events were fatigue, pruritus, and decreased appetite.

Reference

  1. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015. [Epub ahead of print]. doi: 10.1056/NEJMoa1501824.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters